Neuphoria Therapeutics Inc. (NEUP)
US — Healthcare Sector
Peers:
Automate Your Wheel Strategy on NEUP
With Tiblio's Option Bot, you can configure your own wheel strategy including NEUP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NEUP
- Rev/Share 0.0669
- Book/Share 0.1111
- PB 64.3607
- Debt/Equity 0.0066
- CurrentRatio 11.0116
- ROIC 0.0815
- MktCap 13441728.0
- FreeCF/Share -0.0333
- PFCF -1.7253
- PE 291.7165
- Debt/Assets 0.0056
- DivYield 0
- ROE 0.3088
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 2
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck
NEUP
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Milestone payment triggered by the initiation of a Phase 2 clinical trial in Alzheimer's disease with MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator Milestone payment triggered by the initiation of a Phase 2 clinical trial in Alzheimer's disease with MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator
Read More
About Neuphoria Therapeutics Inc. (NEUP)
- IPO Date 2021-12-16
- Website http://www.neuphoriatx.com
- Industry Medical - Pharmaceuticals
- CEO Dr. Spyridon Papapetropoulos M.D., Ph.D.
- Employees 8
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.